NCT01475084

Brief Summary

The purpose of this study is to compare cryobiopsies with forceps biopsies during semirigid thoracoscopy.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
40

participants targeted

Target at P25-P50 for phase_2

Timeline
Completed

Started Nov 2011

Typical duration for phase_2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

November 1, 2011

Completed
15 days until next milestone

First Submitted

Initial submission to the registry

November 16, 2011

Completed
5 days until next milestone

First Posted

Study publicly available on registry

November 21, 2011

Completed
2.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

November 1, 2014

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

November 1, 2014

Completed
Last Updated

September 10, 2015

Status Verified

September 1, 2015

Enrollment Period

3 years

First QC Date

November 16, 2011

Last Update Submit

September 8, 2015

Conditions

Keywords

Flex-rigid pleuroscopycryobiopsypleural biopsypleural effusionsafetythoracoscopy

Outcome Measures

Primary Outcomes (1)

  • Comparison of forceps biopsy and cryobiopsy samples

    * diagnostic yield * size of the biopsy specimens in mm2 * interpretability of biopsy specimens in histopathology terms: 1. easily interpretable (enough tissue with all elements required for diagnosis) 2. interpretable with some difficulty (less tissue or diagnostic elements - diagnosis less reliable) 3. interpretable with great difficulty (little tissue or scarce diagnostic elements - low reliability of diagnosis) 4. non-interpretable (diagnosis not possible) * assessment of biopsy-related artifacts by describing the amount of unaltered tissue in quartiles

    12 month

Secondary Outcomes (1)

  • Safety

    1 month

Study Arms (1)

Cryobiopsy, forceps biopsy

EXPERIMENTAL

Cryoiopsies will be obtained by flexible autoclavable cryoprobe 20416-032 (Erbokryo CA, ERBE, Germany) with 2.4 mm in diameter. The tip of the probe is cooled to -890C with nitrous oxide within seconds after footswitch activation. Forceps biopsies will be obtained by flexible FB-55CD-1 Olympus forceps.

Device: cryobiopsy (Autoclavable cryoprobe 20416-032 (ERBE, Germany) Flexible FB-55CD-1 Olympus forceps

Interventions

The tip of the cryoprobe will be attached to suspicious part of parietal pleura and activated by footswitch for 3 seconds. The frozen tissue is going to be extracted by gently pulling of the probe. The probe with the attached biopsy sample is going to be removed together with the thoracoscope through trocar. The biopsy sample will be released from the probe by thawing in the saline. Forceps biopsy will be performed on usual way.

Also known as: Autoclavable cryoprobe 20416-032 (ERBE, Germany), Flexible FB-55CD-1 Olympus forceps
Cryobiopsy, forceps biopsy

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • or more years old
  • unilateral pleural effusion of unknown origin
  • pleural irregularities suspicious for pleural malignancy
  • referral for thoracoscopy after less invasive means of diagnosis had failed

You may not qualify if:

  • uncontrolled bleeding tendency
  • unstable cardiovascular status
  • severe heart failure
  • ECOG performance status 4
  • persistent hypoxemia after evacuation of pleural fluid
  • pleural symphisis, fibrothorax

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

University Clinic Golnik

Golnik, Golnik, 4204, Slovenia

Location

MeSH Terms

Conditions

Pleural EffusionPleural Diseases

Condition Hierarchy (Ancestors)

Respiratory Tract Diseases

Study Officials

  • Ales Rozman, MD

    University Clinic Golnik

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
phase 2
Allocation
NA
Masking
SINGLE
Who Masked
OUTCOMES ASSESSOR
Purpose
DIAGNOSTIC
Intervention Model
SINGLE GROUP
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
MD

Study Record Dates

First Submitted

November 16, 2011

First Posted

November 21, 2011

Study Start

November 1, 2011

Primary Completion

November 1, 2014

Study Completion

November 1, 2014

Last Updated

September 10, 2015

Record last verified: 2015-09

Locations